SEC Filings
Phathom Must Now Hold $119.3 Million In Cash For Its Royalty Lenders As A Lawsuit Targets VOQUEZNA Exclusivity
The cash floor on Phathom's royalty financing rose from $30 million on October 1, while generic-drug filers challenge its exclusivity.